<DOC>
	<DOC>NCT01464931</DOC>
	<brief_summary>The primary objective was to evaluate the incidence of clinically significant hypocalcemia following multiple 120 mg subcutaneous doses of denosumab in patients with severe chronic kidney disease (CKD) and CKD on dialysis</brief_summary>
	<brief_title>Multiple Dose Study to Evaluate the Safety of Multiple Doses of Denosumab 120 mg in Adults With Severe Chronic Kidney Disease (CKD) and CKD on Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<criteria>Subjects at least 18 years old with severe CKD (defined as creatinine clearance &lt; 30 mL/min at both screening assessments) and CKD requiring hemodialysis Additional inclusion criteria apply Subjects must have calcium, phosphate, and magnesium levels appropriate for their condition and must not have other uncontrolled comorbidities. Additional exclusion criteria apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>